Jean-Pierre Armand MD, MSc, certified in Medical Oncology, is senior consultant at Institut GUSTAVE ROUSSY cancer campus in Paris and visiting professor of oncology in Yunnan University in China.
He is cofounder and CEO of Pegascy, a cancer IGR biotech with the objective of re repurposing drugs discarded in phase 1 by big pharmas.

Until 2012, he was General Director of the Institut Claudius Regaud, the comprehensive cancer center in Toulouse and was in charge of the construction of a new cancer center in a European research hub created in the Toulouse cancer campus (Institut Universitaire du Cancer which opened in 2014).
He is an active member of the Medical Oncology Community.
Previously Head of Early Clinical New Drugs Programs and Medical Director Research and development at the Institut Gustave-Roussy, Villejuif, Dr Armand is involve in Phase I-II and III studies for the treatment of solid tumors and is a permanent support of cancer biotech in oncology in France and abroad.
Dr Armand is active at ESMO, EORTC , at EMEA French agency (ANSM) and in China.
• President of the European Society for Medical Oncology (ESMO) 1993-1995
• Chairman of GTMAC (French branch of EMEA)
• Founder of DITEP (phase 1 clinical trials at IGR)